Prevalence of Neisseria meningitidis serogroups in invasive meningococcal disease in China, 2010 - 2020: a systematic review and meta-analysis

References

• Hill DJ, Griffiths NJ, Borodina E, Virji M. Cellular and molecular biology of Neisseria meningitidis colonization and invasive disease. Clin Sci (Lond). 2010;118(9):547–8. doi:10.1042/CS20090513.
   PubMed Web of Science ®Google Scholar
• Schubert-Unkmeir A. Molecular mechanisms involved in the interaction of Neisseria meningitidis with cells of the human blood-cerebrospinal fluid barrier. Pathog Dis. 2017;75(2). doi:10.1093/femspd/ftx023.
   Web of Science ®Google Scholar
• Wang B, Santoreneos R, Giles L, Haji Ali Afzali H, Marshall H. Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine. 2019;37(21):2768–82. doi:10.1016/j.vaccine.2019.04.020.
   PubMed Web of Science ®Google Scholar
• Olbrich KJ, Müller D, Schumacher S, Beck E, Meszaros K, Koerber F. Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers. Infect Dis Ther. 2018;7(4):421–38. doi:10.1007/s40121-018-0213-2.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Meningococcal meningitis; 2018. https://www.who.int/news-room/fact-sheets/detail/meningitis.
   Google Scholar
• Harrison OB, Claus H, Jiang Y, et al. Description and nomenclature of Neisseria meningitidis capsule locus. Emerg Infect Dis. 2013;19(4):566–73. doi:10.3201/eid1904.111799.
   PubMed Web of Science ®Google Scholar
• Jafri RZ, Ali A, Messonnier NE, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr. 2013;11(1):17. doi:10.1186/1478-7954-11-17.
   PubMed Web of Science ®Google Scholar
• Pelton SI. The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines. J Adolesc Health. 2016;59(2 Suppl):S3–S11. doi:10.1016/j.jadohealth.2016.04.012.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control (ECDC). Invasive meningococcal disease, annual epidemiological report for 2017. https://www.ecdc.europa.eu/sites/default/files/documents/AER_for_2017-invasive-meningococcal-disease.pdf.
   Google Scholar
• Centre for Disease Prevention and Control. Meningococcal disease surveillance. 2021.https://www.cdc.gov/meningococcal/surveillance/.
   Google Scholar
• Lingani C, Bergeron-Caron C, Stuart JM, Fernandez K, Djingarey MH, Ronveaux O, Schnitzler JC, Perea WA. Meningococcal meningitis surveillance in the African meningitis belt, 2004–2013. Clin Infect Dis. 2015;61(Suppl 5):S410–5. doi:10.1093/cid/civ597.
   PubMed Web of Science ®Google Scholar
• Li J, Wu D, Wen N, et al. Serogroup distribution of meningococcal meningitis in China,2015-2019. Chin J Vacc Immunization. 2020;26(2):241–44.
   Google Scholar
• Li J, Shao Z, Liu G, et al. Meningococcal disease and control in China: Findings and updates from the Global Meningococcal Initiative (GMI). J Infect. 2018;76(5):429–37. doi:10.1016/j.jinf.2018.01.007.
   PubMed Web of Science ®Google Scholar
• Shao ZJ, Li W, Ren J, Liang XF, Xu L, Diao BW, et al. Identification of a new Neisseria meningitidis serogroup C clone from Anhui province, China. Lancet. 2006;367(9508):419–23. doi:10.1016/S0140-6736(06)68141-5.
   PubMed Web of Science ®Google Scholar
• Shao Z, Zhou H, Gao Y, Ren H, Xu L, Kan B, Xu J. Neisseria meningitidis Serogroup W135, China. Emerg Infect Dis. 2010;16(2):348–49. doi:10.3201/eid1602.090901.
   PubMed Web of Science ®Google Scholar
• Chen C, Zhang TG, He JG, et al. A first meningococcal meningitis case caused by serogroup X Neisseria meningitidis strains in China. Chin Med J (Engl). 2008;121(7):664–66. doi:10.1097/00029330-200804010-00017.
   PubMed Web of Science ®Google Scholar
• Guo LC, Liu XC, Xu QY, et al. Epidemiological analysis on serogroup Y neisseria meningitidis firstly isolated from patient in Tianjin. Zhonghua Yu Fang Yi Xue Za Zhi. 2016;50(9):825–27. doi:10.3760/cma.j.issn.0253-9624.2016.09.015.
   PubMedGoogle Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906. doi:10.1016/j.ijsu.2021.105906.
   PubMed Web of Science ®Google Scholar
• Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, Baker P, Smith E, Buchbinder R. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol. 2012;65(9):934–39. doi:10.1016/j.jclinepi.2011.11.014.
   PubMed Web of Science ®Google Scholar
• Chen LP, Sun XY, Wei JJ, et al. Epidemiological characteristics of meningococcal meningitis inWenzhou, 2005-2018. Chin J PHM. 2019;35(5):670–78. CNKI:SUN:GGWS.0.2019-05-026.
   Google Scholar
• Wu JH, He TT, Guo TY, et al. Surveillance of cerebrospinal meningitis in Shaoxing from 2005 to 2011. Zhejiang Prevent Med. 2013;25(02):39–41. doi:10.3969/j.issn.1007-0931.2013.02.014.
   Google Scholar
• Shan XY, Bai AY, Liu ZY. Multi locus sequence typing of Neisseria meningitidis in Jinan, Shandong. Dis Surveillance. 2018;33(12):38–42. CNKI:SUN:JBJC.0.2018-12-012.
   Google Scholar
• Feng L, Xiong P, Li MS, et al. Analysis on the epidem iological characteristics and the etiological surveillance for epidem ic cerebrospinal meningitis in Shandong province from 2006 to 2013. Chin J Epidemiol. 2014;35(12):1407–08. doi:10.3760/cma.j.issn.0254-6450.2014.12.021.
   Google Scholar
• Yang M, Zhou HJ, Xu XQ, et al. Serogroup distribution and characteristics of molecular subtyping for Neisseria meningitidis isolated from Jiangxi, 2005-2015. Chin J Zoonoses. 2018;34(11):35–39.
   Google Scholar
• Sun YQ, Ma HS, Jia ZY, et al. Analysis on characteristic and flora change of epidemic cerebrospinal meningitis in Hebei Province. J Med Pest Control. 2012;28(011):1184–87. CNKI:SUN:YXDZ.0.2012-11-001.
   Google Scholar
• He BH, Jia ZY, Wang YT, et al. Study on the surveillance of pathogens and molecular subtyping of meningococcal meningitis cases during 2012-2013 in Hebei province. Chin J Health Lab Tec. 2015;25(005):708–11. CNKI:SUN:ZWJZ.0.2015-05-033.
   Google Scholar
• Jiang F, Zhang L, Zhan W, et al. Epidemiological characteristics of epidemic cerebrospinal meningitis in Guizhou Province from 2011 to 2013. J Publ Health Preve Med. 2014;25(6):80–81. CNKI:SUN:FBYF.0.2014-06-023.
   Google Scholar
• Li J, Li Y, Shao Z, et al. Prevalence of meningococcal meningitis in China from 2005 to 2010. Vaccine. 2015;33(8):1092–97. doi:10.1016/j.vaccine.2014.10.072.
   PubMed Web of Science ®Google Scholar
• Fang LL, Chen H, Xu DC, et al. Analysis of the monitoring of the etiology and serology of epidemic cerebrospinal meningitis from 2014-2016. J Pathogen Biol. 2017;12(09):875–78. doi:10.13350/j.cjpb.170916.
   Google Scholar
• Zhan YH, Luan L, Zhang MH. Analysis on molecular epidemiological characteristics of Neisseria meningitidis in Suzhou, Jiangsu, 2011–2016. Dis Surveillance. 2018;33:640–43.
   Google Scholar
• Wu SW, Liu CT, Wang YY, et al. Multilocus sequence typing of Neisseria meningitis in Guizhou province, 2006-2017. Chin J Vacc Immunization. 2020;26(06):647–65.
   Google Scholar
• Dai DF, Li FJ, Xia X, et al. Epidemiological features of meningococcal meningitis and trend of serogroup switching of Neisseria meningitidis strains in Hunan Province, 1951-2016. Pract Prev Med. 2017;24:1440–42. doi:10.3969/j.issn.1006-3110.2017.12.009.
   Google Scholar
• Purmohamad A, Abasi E, Azimi T, Hosseini S, Safari H, Nasiri MJ, Imani Fooladi AA. Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: a systematic review and meta-analysis. Microb Pathog. 2019;134:103571. doi:10.1016/j.micpath.2019.103571.
   PubMed Web of Science ®Google Scholar
• Parikh SR, Campbell H, Bettinger JA, et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020;81(4):483–98. doi:10.1016/j.jinf.2020.05.079.
   PubMed Web of Science ®Google Scholar
• Mustapha MM, Harrison LH. Vaccine prevention of meningococcal disease in Africa: major advances, remaining challenges. Hum Vaccin Immunother. 2018;14(5):1107–15. doi:10.1080/21645515.2017.1412020.
   PubMed Web of Science ®Google Scholar
• Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol. 2009;9(3):213–20. doi:10.1038/nri2494.
   PubMed Web of Science ®Google Scholar
• Bilukha OO, Rosenstein N. National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54:1–21.
   PubMedGoogle Scholar
• Pizza M, Bekkat-Berkani R, Rappuoli R. Vaccines against Meningococcal diseases. Microorganisms. 2020 Oct 3;8(10):1521. doi:10.3390/microorganisms8101521.
   PubMed Web of Science ®Google Scholar
• Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine. 2001;20(Suppl 1):S58–67. doi:10.1016/s0264-410x(01)00299-7.
   PubMed Web of Science ®Google Scholar
• Borrow R, Abad R, Trotter C, van der Klis FRM, Vazquez JA. Effectiveness of meningococcal serogroup C vaccine programmes. Vaccine. 2013;31(41):4477–86. doi:10.1016/j.vaccine.2013.07.083.
   PubMed Web of Science ®Google Scholar
• Borrow R. Advances with vaccination against Neisseria meningitidis. Trop Med Int Health. 2012;17(12):1478–91. doi:10.1111/j.1365-3156.2012.03085.x.
   PubMed Web of Science ®Google Scholar
• Toneatto D, Pizza M, Masignani V, Rappuoli R. Emerging experience with meningococcal serogroup B protein vaccines. Expert Rev Vaccines. 2017;16(5):433–51. doi:10.1080/14760584.2017.1308828.
   PubMed Web of Science ®Google Scholar
• Masignani V, Pizza M, Moxon ER. The development of a vaccine against Meningococcus B using reverse vaccinology. Front Immunol. 2019;10:751. doi:10.3389/fimmu.2019.00751.
   PubMed Web of Science ®Google Scholar
• Perez JL, Absalon J, Beeslaar J, et al. From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine. Expert Rev Vaccines. 2018;17(6):461–77. doi:10.1080/14760584.2018.1483726.
   PubMed Web of Science ®Google Scholar
• Beeslaar J, Absalon J, Balmer P, et al. Clinical data supporting a 2-dose schedule of MenB-FHbp, a bivalent meningococcal serogroup B vaccine, in adolescents and young adults. Vaccine. 2018;36(28):4004–13. doi:10.1016/j.vaccine.2018.05.060.
   PubMed Web of Science ®Google Scholar
• Parikh SR, Andrews NJ, Beebeejaun K, et al. Effectiveness and impact of a reduced infant schedule of 4cmenb vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet. 2016;388(10061):2775–82. doi:10.1016/S0140-6736(16)31921-3.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Andrews N, Parikh SR, et al. Vaccination of infants with Meningococcal group B vaccine (4cmenbf) in England. N Engl J Med. 2020;382(4):309–17. doi:10.1056/NEJMoa1901229.
   PubMed Web of Science ®Google Scholar